Graft versus host disease

This early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…

Infants with severe combined immunodeficiency (SCID) lack working immune cells and face life-threatening infections. A matched sibling donor transplant is the standard cure, but most babies do not have one. This trial tests a refined transplant using a parent or other partially m…

This trial tests a modified stem cell transplant for people with severe sickle cell disease or beta-thalassemia who are at higher risk of transplant failure. The approach uses low-dose radiation and a mix of immunosuppressive drugs to help the body accept donor stem cells without…

This phase II trial tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body, causing serious symptoms. Axatilimab is…

This trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This early-phase study tests whether drinking milk from genetically engineered goats (which produce a human enzyme found in breast milk) can reduce the risk of graft versus host disease—a serious immune reaction—in blood cancer patients receiving a donor stem cell transplant. Abo…

This trial tests leflunomide, a drug used for rheumatoid arthritis, in people with chronic graft-versus-host disease (cGVHD) who depend on steroids. cGVHD is a complication of bone marrow transplant where donor immune cells attack the recipient's body. The goal is to see if leflu…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study tests a new treatment called CYP-001 for people who develop a severe immune reaction (graft versus host disease) after a stem cell transplant. About 60 participants will receive either CYP-001 plus standard steroids or a placebo plus steroids. The goal is to see if add…

This trial tests whether infusions of white blood cells from healthy, unrelated donors can help treat solid cancers that have not responded to standard treatments. About 29 patients will receive daily infusions over 1-2 weeks, and their tumors will be checked after 3 months. The …

This study tests a stem cell transplant using cells from a half-matched family donor, combined with low-dose radiation and drugs to prevent rejection, for adults with severe sickle cell disease or beta-thalassemia. The goal is to see if this gentler approach can replace the disea…

This study tests a stem cell transplant from a half-matched relative (haploidentical donor) for adults with severe sickle cell disease. The goal is to see if a gentler conditioning regimen can reduce complications like graft rejection and graft-versus-host disease. Participants r…

This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival wit…

This phase II trial tests a special stem cell transplant that removes immune T-cells from the donor's blood to lower the risk of graft-versus-host disease (GVHD), a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic syndrome…

This study tests whether adding the drug abatacept to standard care can prevent graft-versus-host disease (GVHD) in children receiving stem cell transplants from unrelated donors. GVHD occurs when donor cells attack the patient's body, causing serious illness. The trial will enro…

This study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells …

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to re…

This phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can reduce side effects while still preventing the donor cells from attacking the recipient's body. The trial includes 105 people aged 15-65 with blood cancers like leukemia or…

This study aimed to see if lower doses of chemotherapy drugs, with or without radiation, could safely prepare children and adults with SCID for a stem cell transplant. The goal was to help the donor cells take hold while avoiding severe side effects. However, the trial was withdr…

This study tests whether daily intravenous omega-3 fatty acids (fish oil) can reduce the risk and severity of acute graft-versus-host disease (aGVHD) in 30 adults receiving a stem cell transplant. Participants get omega-3 infusions from before transplant until about 35 days after…

This early-phase study tests a new treatment called CD6-CAR Tregs for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The treatment uses specially engineered immune cells from a donor to help control the immune attack on the pat…

This study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…

This study offers continued access to ibrutinib for people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and are still benefiting from the drug but cannot get it commercially. About 297 participants will receive ibrutinib while res…

This early-phase trial aimed to test whether adding the drug 5-azacytidine (AZA) to standard steroid treatment could protect gut stem cells in patients with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. The study pla…

This study tests whether a group-based behavioral program called Horizons can improve quality of life and coping skills in adults with chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplant. The program involves 8 weekly video sessions with a …

This study tests whether 30 sessions of UVA-1 light therapy can improve daily life for people with scleroderma, morphea, or skin hardening from graft-versus-host disease. Thirty adults will report how their symptoms affect everyday tasks before and after treatment. The goal is to…

This study tests a telehealth program called Horizons for adults who have had a stem cell transplant and developed moderate to severe chronic graft-versus-host disease (GVHD). The program uses video sessions and questionnaires to help patients cope and follow their treatment plan…

This study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term s…

This study aims to create a symptom questionnaire specifically for children and teens living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Current symptom scales are designed for adults, but children may describe their symptoms differently. Research…

This study follows 250 people who have had a donor stem cell transplant to see if respiratory viruses lead to a lung condition called bronchiolitis obliterans syndrome (BOS). Participants use a handheld device at home to measure lung function and provide nasal swabs and blood sam…

This study examines tissue samples from patients who developed graft-versus-host disease (GVHD) after a stem cell transplant. Researchers use a technology called nCounter to measure the activity of 800 immune-related genes in these samples. The goal is to identify a unique molecu…

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study aims to better understand what causes inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), and other gut problems by analyzing blood and tissue samples from 1,000 patients. Researchers will use advanced lab techniques to track immune system changes over …

This study looks at how changes in gut bacteria and their byproducts after a stem cell transplant might influence the development of graft-versus-host disease (GVHD), a serious complication. Researchers will collect stool and blood samples from 88 transplant recipients and their …

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…